Quantitative prediction of renal transporter-mediated clinical drug-drug interactions

Molecular Pharmaceutics

Volumn 10, Issue 11, 2013, Pages 4207-4215

  Feng, Bo ^a   Hurst, Susan ^a   Lu, Yasong ^b   Varma, Manthena V ^a   Rotter, Charles J ^a   El Kattan, Ayman ^a   Lockwood, Peter ^a   Corrigan, Brian ^a  

^a PFIZER INC   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

Author keywords

cimetidine; drug drug interaction; probenecid; renal clearance; renal transporters

Indexed keywords

ACICLOVIR; ADRENERGIC RECEPTOR STIMULATING AGENT; ANTIVIRUS AGENT; BUMETANIDE; CEFALEXIN; CEFAMANDOLE; CENTRAL STIMULANT AGENT; CIDOFOVIR; CIMETIDINE; CIPROFLOXACIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FAMOTIDINE; FUROSEMIDE; GANCICLOVIR; IMAGABALIN; METFORMIN; METHOTREXATE; ORGANIC ANION TRANSPORTER; ORGANIC CATION TRANSPORTER; OSELTAMIVIR; PD 0299685; PREGABALIN; PROBENECID; PROCAINAMIDE; RANITIDINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VARENICLINE; ZALCITABINE; ZIDOVUDINE;

AREA UNDER THE CURVE; ARTICLE; DRUG CLEARANCE; DRUG INTERACTION; DRUG STRUCTURE; HOSPITAL; HUMAN; HUMAN CELL; IN VITRO STUDY; KIDNEY CLEARANCE; PHARMACOKINETICS; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS;

AREA UNDER CURVE; CELL LINE; CIMETIDINE; DRUG INTERACTIONS; HUMANS; KIDNEY; MASS SPECTROMETRY; MEMBRANE TRANSPORT PROTEINS; MODELS, THEORETICAL; PROBENECID;

EID: 84887333687     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp400295c     Document Type: Article

References (56)

1. Varma, M. V. S.; Feng, B.; Obach, R. S.; Troutman, M. D.; Chupka, J.; Miller, H. R.; El-Kattan, A. Physicochemical Determinants of Human Renal Clearance J. Med. Chem. 2009, 52 (15) 4844-4852
2. Feng, B.; LaPerle, J. L.; Chang, G.; Varma, M. V. Renal clearance in drug discovery and development: molecular descriptors, drug transporters and disease state Expert Opin. Drug Metab. Toxicol. 2010, 6 (8) 939-952
3. Dresser, M. J.; Leabman, M. K.; Giacomini, K. M. Transporters involved in the elimination of drugs in the kidney: Organic anion transporters and organic cation transporters J. Pharm. Sci. 2001, 90 (4) 397-421
4. Bednarczyk, D.; Ekins, S.; Wikel, J. H.; Wright, S. H. Influence of Molecular Structure on Substrate Binding to the Human Organic Cation Transporter, hOCT1 Mol. Pharmacol. 2003, 63 (3) 489-498
5. Ullrich, K. J.; Rumrich, G.; Burke, T. R.; Shirazi-Beechey, S. P.; Lang, H.-J. Interaction of Alkyl/Arylphosphonates, Phosphonocarboxylates and Diphosphonates with Different Anion Transport Systems in the Proximal Renal Tubule J. Pharmacol. Exp. Ther. 1997, 283 (3) 1223-1229
6. Ci, L.; Kusuhara, H.; Adachi, M.; Schuetz, J. D.; Takeuchi, K.; Sugiyama, Y. Involvement of MRP4 (ABCC4) in the Luminal Efflux of Ceftizoxime and Cefazolin in the Kidney Mol. Pharmacol. 2007, 71 (6) 1591-1597
7. Shitara, Y.; Horie, T.; Sugiyama, Y. Transporters as a determinant of drug clearance and tissue distribution Eur. J. Pharm. Sci. 2006, 27 (5) 425-446
8. Masereeuw, R.; Russel, F. G. Mechanisms and clinical implications of renal drug excretion Drug Metab. Rev. 2001, 33 (3-4) 299-351
9. Aherne, G. W.; Piall, E.; Marks, V.; Mould, G.; White, W. F. Prolongation and enhancement of serum methotrexate concentrations by probenecid Br. Med. J. 1978, 1 (6120) 1097-1099
10. Feng, B.; Obach, R. S.; Burstein, A. H.; Clark, D. J.; de Morais, S. M.; Faessel, H. M. Effect of Human Renal Cationic Transporter Inhibition on the Pharmacokinetics of Varenicline, a New Therapy for Smoking Cessation: An In Vitro-In Vivo Study Clin. Pharmacol. Ther. 2008, 83 (4) 567-576
11. Kanai, Y.; Segawa, H.; Miyamoto, K.; Uchino, H.; Takeda, E.; Endou, H. Expression Cloning and Characterization of a Transporter for Large Neutral Amino Acids Activated by the Heavy Chain of 4F2 Antigen (CD98) J. Biol. Chem. 1998, 273 (37) 23629-23632
12. Varma, M. V.; Gardner, I.; Steyn, S. J.; Nkansah, P.; Rotter, C. J.; Whitney-Pickett, C.; Zhang, H.; Di, L.; Cram, M.; Fenner, K. S.; El-Kattan, A. F. pH-Dependent Solubility and Permeability Criteria for Provisional Biopharmaceutics Classification (BCS and BDDCS) in Early Drug Discovery Mol. Pharmaceutics 2012, 9 (5) 1199-1212
13. Rowland, M.; Matin, S. B. Kinetics of drug-drug interactions J. Pharmacokinet. Biopharm. 1973, 1, 553-567
14. Takeda, M.; Narikawa, S.; Hosoyamada, M.; Cha, S. H.; Sekine, T.; Endou, H. Characterization of organic anion transport inhibitors using cells stably expressing human organic anion transporters Eur. J. Pharmacol. 2001, 11 (419) 113-120
15. Emanuelsson, B. M.; Beermann, B.; Paalzow, L. K. Non-linear elimination and protein binding of probenecid Eur. J. Clin. Pharmacol. 1987, 32 (4) 395-401
16. Motohashi, H.; Uwai, Y.; Hiramoto, K.; Okuda, M.; Inui, K.-i. Different transport properties between famotidine and cimetidine by human renal organic ion transporters (SLC22A) Eur. J. Clin. Pharmacol. 2004, 503 (1-3) 25-30
17. Inotsume, N.; Nishimura, M.; Nakano, M.; Fujiyama, S.; Sato, T. The inhibitory effect of probenecid on renal excretion of famotidine in young, healthy volunteers J. Clin. Pharm. 1990, 30 (1) 50-56
18. Koepsell, H.; Lips, K.; Volk, C. Polyspecific organic cation transporters: structure, function, physiological roles, and biopharmaceutical implications Pharm. Res. 2007, 24, 1227-1251
19. Sitsen, J. M.; Maris, F. A.; Timmer, C. J. Concomitant use of mirtazapine and cimetidine: a drug-drug interaction study in healthy male subjects Eur. J. Clin. Pharmacol. 2000, 56 (5) 389-394
20. Su, T. Z.; Feng, M. R.; Weber, M. L. Mediation of Highly Concentrative Uptake of Pregabalin by L-Type Amino Acid Transport in Chinese Hamster Ovary and Caco-2 Cells J. Pharmacol. Exp. Ther. 2005, 313 (3) 1406-1415
21. Tsuda, M.; Terada, T.; Ueba, M.; Sato, T.; Masuda, S.; Katsura, T.; Inui, K.-i. Involvement of Human Multidrug and Toxin Extrusion 1 in the Drug Interaction between Cimetidine and Metformin in Renal Epithelial Cells J. Pharmacol. Exp. Ther. 2009, 329 (1) 185-191
22. Tanihara, Y.; Masuda, S.; Sato, T.; Katsura, T.; Ogawa, O.; Inui, K.-i. Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H+-organic cation antiporters Biochem. Pharmacol. 2007, 74 (2) 359-371
23. Field, M. J.; Cox, P. J.; Stott, E.; Melrose, H.; Offord, J.; Su, T.-Z.; Bramwell, S.; Corradini, L.; England, S.; Winks, J.; Kinloch, R. A.; Hendrich, J.; Dolphin, A. C.; Webb, T.; Williams, D. Identification of the α2-δ-1 subunit of voltage-dependent calcium channels as a molecular target for pain mediating the analgesic actions of pregabalin Proc. Natl. Acad. Sci. 2006, 103 (46) 17537-17542
24. Taylor, C. P.; Angelotti, T.; Fauman, E. Pharmacology and mechanism of action of pregabalin: The calcium channel [alpha]2-[delta] (alpha2-delta) subunit as a target for antiepileptic drug discovery Epilepsy Res. 2007, 73 (2) 137-150
25. Randinitis, E. J.; Posvar, E. L.; Alvey, C. W.; Sedman, A. J.; Cook, J. A.; Bockbrader, H. N. Pharmacokinetics of Pregabalin in Subjects with Various Degrees of Renal Function J. Clin. Pharmacol. 2003, 43 (3) 277-283
26. Obach, R. S. Predicting drug-drug interactions from in vitro drug metabolism data: challenges and recent advances Curr. Opin. Drug Discovery Dev. 2009, 12 (1) 81-89
27. Laskin, O. L.; de Miranda, P.; King, D. H.; Page, D. A.; Longstreth, J. A.; Rocco, L.; Lietman, P. S. Effects of probenecid on the pharmacokinetics and elimination of acyclovir in humans Antimicrob. Agents Chemother. 1982, 21 (5) 804-807
28. Odlind, B.; Beermann, B.; Lindström, B. Coupling between renal tubular secretion and effect of bumetanide Clin. Pharmacol. Ther. 1983, 34 (6) 805-809
29. Griffith, R. S.; Black, H. R.; Brier, G. L.; Wolny, J. D. Effect of Probenecid on the Blood Levels and Urinary Excretion of Cefamandole Antimicrob. Agents Chemother. 1977, 11 (5) 809-812
30. Sennello, L. T.; Quinn, D.; Rollins, D. E.; Tolman, K. G.; Sonders, R. C. Effect of probenecid on the pharmacokinetics of cefmenoxime Antimicrob. Agents Chemother. 1983, 23 (6) 803-807
31. Cundy, K. C.; Petty, B. G.; Flaherty, J.; Fisher, P. E.; Polis, M. A.; Wachsman, M.; Lietman, P. S.; Lalezari, J. P.; Hitchcock, M. J.; Jaffe, H. S. Clinical pharmacokinetics of cidofovir in human immunodeficiency virus-infected patients Antimicrob. Agents Chemother. 1995, 39 (6) 1247-1252
32. Gisclon, L. G.; Boyd, R. A.; Williams, R. L.; Giacomini, K. M. The effect of probenecid on the renal elimination of cimetidine Clin. Pharmacol. Ther. 1989, 45 (4) 444-452
33. Israel, K.; Black, H.; Nelson, R.; Brunson, M.; Nash, J.; Brier, G.; Wolney, J. Cinoxacin: pharmacokinetics and the effect of probenecid J. Clin. Pharmacol. 1978, 18 (10) 491-499
34. Jaehde, U.; Sorgel, F.; Reiter, A.; Sigl, G.; Naber, K. G.; Schunack, W. Effect of probenecid on the distribution and elimination of ciprofloxacin in humans Clin. Pharmacol. Ther. 1995, 58 (5) 532-541
35. Noormohamed, F. H.; McNabb, W. R.; Lant, A. F. Pharmacokinetic and pharmacodynamic actions of enalapril in humans: effect of probenecid pretreatment J. Pharmacol. Exp. Ther. 1990, 253 (1) 362-368
36. Liu, S.; Beringer, P. M.; Hidayat, L.; Rao, A. P.; Louie, S.; Burckart, G. J.; Shapiro, B. Probenecid, but Not Cystic Fibrosis, Alters the Total and Renal Clearance of Fexofenadine J. Clin. Pharmacol. 2008, 48 (8) 957-965
37. Chennavasin, P.; Seiwell, R.; Brater, D. C.; Liang, W. M. Pharmacodynamic analysis of the furosemide-probenecid interaction in man Kidney Int. 1979, 16 (2) 187-195
38. Cimoch, P. J.; Lavelle, J.; Pollard, R.; Griffy, K. G.; Wong, R.; Tarnowski, T. L.; Casserella, S.; Jung, D. Pharmacokinetics of oral ganciclovir alone and in combination with zidovudine, didanosine, and probenecid in HIV-infected subjects J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 1998, 17 (3) 227-234
39. Waller, E.; Sharanevych, M.; Yakatan, G. The effect of probenecid on nafcillin disposition J. Clin. Pharmacol. 1982, 22 (10) 482-489
40. Hill, G.; Cihlar, T.; Oo, C.; Ho, E. S.; Prior, K.; Wiltshire, H.; Barrett, J.; Liu, B.; Ward, P. The Anti-Influenza Drug Oseltamivir Exhibits Low Potential to Induce Pharmacokinetic Drug Interactions via Renal Secretion-Correlation of in Vivo and in Vitro Studies Drug Metab. Dispos. 2002, 30 (1) 13-19
41. Massarella, J. W.; Nazareno, L. A.; Passe, S.; Min, B. The Effect of Probenecid on the Pharmacokinetics of Zalcitabine in HIV-Positive Patients Pharm. Res. 1996, 13 (3) 449-452
42. Hedaya, M. A.; Elmquist, W. F.; Sawchuk, R. J. Probenecid Inhibits the Metabolic and Renal Clearances of Zidovudine (AZT) in Human Volunteers Pharm. Res. 1990, 7 (4) 411-417
43. De Bony, F.; Tod, M.; Bidault, R.; On, N. T.; Posner, J.; Rolan, P. Multiple Interactions of Cimetidine and Probenecid with Valaciclovir and Its Metabolite Acyclovir Antimicrob. Agents Chemother. 2002, 46 (2) 458-463
44. Somogyi, A. A.; Hovens, C. M.; Muirhead, M. R.; Bochner, F. Renal tubular secretion of amiloride and its inhibition by cimetidine in humans and in an animal model Drug Metab. Dispos. 1989, 17 (2) 190-196
45. van Crugten, J.; Bochner, F.; Keal, J.; Somogyi, A. Selectivity of the cimetidine-induced alterations in the renal handling of organic substrates in humans. Studies with anionic, cationic and zwitterionic drugs J. Pharmacol. Exp. Ther. 1986, 236 (2) 481-487
46. Abel, S.; Nichols, D. J.; Brearley, C. J.; Eve, M. D. Effect of cimetidine and ranitidine on pharmacokinetics and pharmacodynamics of a single dose of dofetilide Br. J. Clin. Pharmacol. 2000, 49 (1) 64-71
47. Yasui-Furukori, N.; Uno, T.; Sugawara, K.; Tateishi, T. Different Effects of Three Transporting Inhibitors, Verapamil, Cimetidine, and Probenecid, on Fexofenadine Pharmacokinetics Clin. Pharmacol. Ther. 2005, 77 (1) 17-23
48. Wang, Z.-J.; Yin, O. Q. P.; Tomlinson, B.; Chow, M. S. S. OCT2 polymorphisms and in-vivo renal functional consequence: studies with metformin and cimetidine Pharmacogenet. Genom. 2008, 18 (7) 637-645
49. Somogyi, A.; Muirhead, M. Pharmacokinetic Interactions of Cimetidine 1987 Clin. Pharmacokinet. 1987, 12 (5) 321-366
50. Rodvold, K. A.; Paloucek, F. P.; Jung, D.; Gallastegui, J. Interaction of steady-state procainamide with H2-receptor antagonists cimetidine and ranitidine Ther. Drug Monit. 1987, 9 (4) 378-383
51. Christian, C. D. J.; Meredith, C. G.; Speeg, K. V. J. Cimetidine inhibits renal procainamide clearance Clin. Pharmacol. Ther. 1984, 36 (2) 221-227
52. Somogyi, A.; McLean, A.; Heinzow, B. Cimetidine-procainamide pharmacokinetic interaction in man: evidence of competition for tubular secretion of basic drugs Eur. J. Clin. Pharmacol. 1983, 25 (3) 339-345
53. Fletcher, C. V.; Henry, W. K.; Noormohamed, S. E.; Rhame, F. S.; Balfour, H. H. J. The effect of cimetidine and ranitidine administration with zidovudine Pharmacother. 1995, 15 (6) 701-708
54. Bockbrader, H. N. Clinical Pharmacokinetics of Gabapentin Drugs Today 1995, 31 (8) 613-619
55. Bockbrader, H. N.; Radulovic, L. L.; Posvar, E. L.; Strand, J. C.; Alvey, C. W.; Busch, J. A.; Randinitis, E. J.; Corrigan, B. W.; Haig, G. M.; Boyd, R. A.; Wesche, D. L. Clinical pharmacokinetics of pregabalin in healthy volunteers J. Clin. Pharmacol. 2010, 50 (8) 941-950
56. Gidal, B. E.; DeCerce, J.; Bockbrader, H. N.; Gonzalez, J.; Kruger, S.; Pitterle, M. E.; Rutecki, P.; Ramsay, R. E. Gabapentin bioavailability: effect of dose and frequency of administration in adult patients with epilepsy Epilepsy Res. 1998, 31 (2) 91-99